Publication

Article

Pharmacy Times

September 2014 Oncology
Volume80
Issue 9

Respiratory Diseases Carry Increased Risk for Lung Cancer

Various common respiratory diseases carry with them an increased risk of lung cancer, according to the results of a study published on August 15, 2014, in the American Journal of Respiratory and Critical Care Medicine.

In a large pooled analysis of 7 studies involving more than 25,000 patients, 12,500 cases, and 14,900 controls, researchers found associations between lung cancer and chronic bronchitis, emphysema, and pneumonia. There was an increased risk for lung cancer in patients with all 3 respiratory conditions.

The most often reported previous respiratory diseases in the study were pneumonia and chronic bronchitis. In adjusting for other respiratory diseases and smoking, positive associations with lung cancer were found most prominently between chronic bronchitis and emphysema. The odds ratio among men was 1.33 for bronchitis and 1.50 for emphysema.

The study also showed a positive association with lung cancer in pneumonia cases that had been diagnosed 2 or fewer years previously. Asthma, however, had an inverse association with the risk of developing lung cancer, while no association was found between tuberculosis and lung cancer.

A higher risk for lung cancer was found in patients with cooccurring chronic bronchitis, emphysema, and pneumonia than in those with chronic bronchitis alone.

Related Videos
Senior Doctor is examining An Asian patient.
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC